News

Capricor Therapeutics Faces Class Action Amid FDA Challenges

Capricor Therapeutics Faces Class Action Amid FDA Challenges

Introduction to Capricor Therapeutics

Capricor Therapeutics, Inc. is a company known for its innovative therapies targeting serious diseases. Recently, the company has been under scrutiny due to a class action lawsuit concerning its lead product, deramiocel, which aims to treat cardiomyopathy related to Duchenne muscular dystrophy (DMD). Investors are urged to pay attention, as the lawsuit concerns substantial losses over a specific period.

Background of the Lawsuit

The class action lawsuit filed on behalf of investors alleges that during a particular timeframe, Capricor misled the market regarding its prospects for a Biologics License Application (BLA) approval by the FDA. The lawsuit aims to cover losses experienced from the date of October 9, 2024, until July 10, 2025. These allegations center around misleading statements that obscured the company's struggles with the FDA's approval process.

Key Allegations Against Capricor

According to the allegations, Capricor provided optimistic projections regarding the FDA's evaluation of its drug, deramiocel. However, it is claimed that the company failed to disclose critical information regarding negative data from its Phase 2 HOPE-2 trial. These disclosures were crucial for investors, as the FDA later issued a Complete Response Letter (CRL) denying the BLA submission, citing insufficient evidence of effectiveness. The stock price was significantly affected, plunging after the press release from Capricor.

The Impact of the FDA's Response

Following the FDA's issuance of the CRL on July 11, 2025, Capricor's stock experienced a notable decline. With the price dropping from $11.40 to $7.64 per share, many investors faced significant financial losses. This sudden downturn serves as a cautionary tale for future investors regarding the importance of transparency in communications between a company and its investors.

Next Steps for Affected Investors

Affected investors have until September 15, 2025, to file a motion for their appointment as lead plaintiff in this class action. Participating in this lawsuit is crucial for those who suffered losses, as it is an opportunity to seek recovery without any upfront costs. It's important to act promptly and gather necessary documentation related to their investments in Capricor.

Why Choose Levi & Korsinsky for Representation?

Levi & Korsinsky, LLP has a strong reputation in securities litigation, having secured substantial recoveries for numerous investors over the years. Their legal team possesses vast experience and specializes in complex securities cases, ensuring that clients receive knowledgeable representation throughout the lawsuit process. Their continued success in the field makes them a trusted choice for investors looking to navigate these turbulent waters.

Conclusion and Contact Information

If you are an investor in Capricor Therapeutics who has been affected by their recent developments, now is the time to take action. You can reach out to Levi & Korsinsky, LLP for further guidance on participating in the class action lawsuit. Contact Joseph E. Levi, Esq. at their office directly via phone at (212) 363-7500 or through email for personalized support.

Frequently Asked Questions

What is the class action lawsuit against Capricor about?

The lawsuit alleges that Capricor misled investors regarding the approval process of its lead drug, deramiocel, leading to significant financial losses.

Who can participate in the lawsuit?

Any investor who acquired shares of Capricor Therapeutics between October 9, 2024, and July 10, 2025, can participate, especially if they suffered losses during this time.

What is the deadline to join the class action?

The deadline for affected investors to request being appointed as lead plaintiff is September 15, 2025.

Is there a cost to join the lawsuit?

No, there is no obligation or upfront cost to participate in the lawsuit if you qualify as a class member.

Who should I contact for more information?

You can contact Levi & Korsinsky, LLP, specifically Joseph E. Levi at (212) 363-7500, for more details on the lawsuit and your potential involvement.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Finzly Welcomes Paul Finch to Drive BankOS Growth

Updated Category News Views 42

Finzly's Strategic Move to Boost Innovation Alright, folks, it seems Finzly means business. They just roped in Paul Finch, the brains who gave us Zelle during his stint as CEO over at Early Warning Services. This guy's been around the block with a couple of the biggest names in banking, and if his past headlines are any indicator, he's got the knack for shaking things up...

Continue Reading
Concierto's Azure Push Puts Sovereignty on Display

Updated Category News Views 78

Sovereignty has become the corporate cloud world's favorite hard-edged word. Concierto is taking that word straight onto the Microsoft Ignite 2026 floor, and frankly, it is a sensible place to make the case. The company, part of Trianz, will appear as a Gamechanger Sponsor from November 17 through 20 at San Francisco's Moscone Center, showing its platform at Booth #5435....

Continue Reading
Thoughts Unleashed Arrives With a Personal American Voice

Updated Category News Views 114

A lifetime of observation finally gets its own page Forty is an unusual age to begin writing poetry, which is exactly why Joyce Ann Grooms McGeehan's debut has a little more texture than the usual polished promise of inspiration. Thoughts Unleashed by an Independent, American Woman comes from someone who spent decades teaching French, English, and ESL, then retired to a...

Continue Reading
Red Cat Stock Drama: Revenue Targets and Legal Waves

Updated Category News Views 110

Red Cat's Revenue Predictions Crash and Burn Sitting there on August 6, 2026, Red Cat Holdings had everyone believing they were on a fast track to hitting a hefty revenue target: $150–$180 million for FY2026. CEO Jeffrey Thompson didn't mince words, boasting confidence like a captain before a storm. Fast forward three months, and they're waving the white flag, tossing...

Continue Reading
ZTO's Pricing Muscle Shows Up in Third-Quarter Results

Updated Category News Views 136

Ten billion parcels can hide plenty of ugly economics, but ZTO's third quarter does not look like a volume-at-any-cost stunt. The company moved 10.241 billion parcels, up 7.0% from a year earlier, and says that outpaced the industry by 4.1 percentage points. More importantly, revenue climbed 21.0% to RMB14.36 billion while adjusted net income reached RMB2.57 billion. That...

Continue Reading
Onward Therapeutics Secures $28M to Bolster Oncology R&D

Updated Category News Views 76

Cashing In to Conquer Cancer In the risk-laden world of biotech, Onward Therapeutics has just bagged a hefty NT$900 million—roughly US$28 million—from its Series B financing. That's not pocket change and speaks to the level of confidence their backers have, even as they plant their global headquarters firmly in Taipei since relocating from Switzerland. A Deep Dive...

Continue Reading
Snowhawk Enters Telarus as Digital Demand Gets Serious

Updated Category News Views 68

Telarus just pulled another serious capital partner into the room, and that matters more than the usual law-firm victory lap. Snowhawk Partners has invested in the technology services distributor alongside Columbia Capital, which remains a long-standing partner. Nobody disclosed a valuation, ownership percentage, financing mix, or closing date. Annoying? Sure. But the...

Continue Reading
A Decade of Giving: Light the World Initiative's Impact

Updated Category News Views 80

The Red Kiosk Revolution It's not every day that a church initiative pops up in global conversations, but here we are—ten years into the Light the World initiative by The Church of Jesus Christ of Latter-day Saints. What's interesting is how these little kiosks, like silent ambassadors, have become a staple in 145 spots this holiday season, spanning continents. Each...

Continue Reading
Caracal’s $200K VMI Pledge Targets Cadet Affordability

Updated Category News Views 160

A tuition award can still leave a brutal hole in the budget. That is the plain fact sitting underneath Caracal Products & Services’ $200,000 commitment to Virginia Military Institute. Federal ROTC scholarships can cover tuition, but VMI says room, board and quartermaster fees average about $15,000 annually. For a student who has done everything right—earned the ROTC...

Continue Reading
Spruce Spins Adrenyx En Route to Nasdaq in 2027

Updated Category News Views 114

New Frontiers: Adrenyx Biosciences Takes Shape Well, here's a new chapter in biotech drama. Spruce Biosciences, a name you might have tangled with if you're into tickers like NASDAQ:SPRB, just carved out a niche with the birth of Adrenyx Biosciences. The play? A separate company eyeing the endocrinology space, setting its sights on tackling congenital adrenal hyperplasia...

Continue Reading

Top 5 Most Recently Viewed Articles

Important Update for Investors in Metagenomi Class Action

Updated Category News Views 103

Key Deadline for Metagenomi Investors As investors in Metagenomi, Inc. keep a close watch, an important deadline is approaching. The time to file a lead plaintiff motion in the class action lawsuit is set for November 25, 2024. This action is vital for those who purchased or acquired Metagenomi securities, specifically those linked to the company’s latest initial public...

Continue Reading
Structure Therapeutics Engages with Investors at Key Conferences

Updated Category News Views 78

Structure Therapeutics Engages with Investors at Key Conferences Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company, is gearing up to participate in important investor conferences this September. The company is dedicated to developing innovative oral small molecule therapeutics aimed at treating metabolic and cardiopulmonary...

Continue Reading
OmaSp Reports Solid Financial Performance with Growth Prospects

Updated Category News Views 156

OmaSp's Strong Financial Performance and Future Outlook OMA SAVINGS BANK PLC has recently released its financial statements for the year ending December 31, 2024, showing promising results and projections for continued growth. Known as OmaSp, the bank reported a noteworthy fourth quarter, aligning with the expectations set forth at the beginning of the year, and a solid...

Continue Reading
Unveiling the Reagan National Economic Forum for Future Growth

Updated Category News Views 485

Reagan National Economic Forum Set to Inspire Economic Solutions The Ronald Reagan Presidential Foundation and Institute is gearing up for a transformative inaugural economic summit with leading figures from the business and economic policy landscapes to take place in late May 2025. About the Forum’s Objectives The Reagan National Economic Forum (RNEF) aims to provide a...

Continue Reading
Experience the Vibrant Latin Business Networking Event of 2025

Updated Category News Views 279

Celebrating the Latino Business Community Prepare yourself for an unforgettable networking event dedicated to the Latino business community, brought to you by Latin Biz Today and Mercy University. The Spectrum of Success event promises a night filled with excitement, learning, and cultural experiences that will leave a lasting impression on everyone involved. A Night of...

Continue Reading